Hexahydro-6,7-dihydroxy-5-(hydroxymethyl)-3-(2-hydroxyphenyl)-2H-pyrano[2,3-d]oxazol-2-one

Metabolite details

Identifier

XBYMZYWXQBJAJG-UHFFFAOYSA-N

InChI Key

XBYMZYWXQBJAJG-UHFFFAOYSA-N

IUPAC name

6,7-dihydroxy-5-(hydroxymethyl)-3-(2-hydroxyphenyl)-5,6,7,7a-tetrahydro-3aH-pyrano[2,3-d][1,3]oxazol-2-one

Preferred name

Hexahydro-6,7-dihydroxy-5-(hydroxymethyl)-3-(2-hydroxyphenyl)-2H-pyrano[2,3-d]oxazol-2-one

INN name

—

Synonym

—

ChEBI

CHEBI:174830

Reactome pathways

• No Reactome pathways listed for this metabolite.

Observed in studies

• Hfq Regulates Efflux Pump Expression and Purine Metabolic Pathway to Increase the Trimethoprim Resistance in Aeromonas veronii
• Bioaccumulation of therapeutic drugs by human gut bacteria: cross-feeding metabolite analysis (FIA-MS) (E.rectale;S.salivarius assays)
• Metabolic Dynamics of In Vitro CD8+ T Cell Activation.
• Multi-Omics Analysis Reveals Disturbance of Nanosecond Pulsed Electric Field in the Serum Metabolic Spectrum and Gut Microbiota
• Diallyl disulfide (DADS) ameliorates intestinal Candida albicans infection by modulating the gut microbiota and metabolites and providing intestinal protection in mice

Observed in differential profiles

• Wild_type_vs_hfq
• G4_Eubacterium_rectale_DMSO_30_vs_G3_Eubacterium_rectale_Duloxetine_47
• G3_Experimental_Sample_0h_vs_G11_Experimental_Sample_96h
• G3_Experimental_Sample_0h_vs_G11_Experimental_Sample_96h
• Control_vs_nsPEF_7_day
• G1_PBS_vs_G2_DSS